Senzime (SEZI) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
28 Nov, 2025Executive summary
Net sales grew 94% year-over-year to SEK 23.5 million in Q1 2025, driven by the launch of the next-generation TetraGraph system and strong sensor sales growth, especially in the U.S. and Europe.
Over 440 TetraGraph systems delivered in Q1, nearly half the total delivered in all of 2024.
Gross margin before depreciation improved to 65.9% from 64.3% in Q1 2024, due to better pricing and reduced manufacturing costs.
Operating expenses remained stable despite commercial expansion and increased production capacity.
EBITDA loss narrowed to SEK -20.8 million from SEK -28.5 million year-over-year, showing significant improvement toward profitability.
Financial highlights
Net sales: SEK 23,499 thousand (Q1 2024: SEK 12,120 thousand), up 94%, with sensor unit deliveries up over 100%.
Gross profit excl. amortization: SEK 15,485 thousand (Q1 2024: SEK 7,798 thousand); gross margin excl. amortization: 65.9% (Q1 2024: 64.3%).
EBITDA: SEK -20,839 thousand (Q1 2024: SEK -28,546 thousand).
Earnings per share: SEK -0.27 (Q1 2024: SEK -0.23).
Cash and cash equivalents: SEK 62,059 thousand as of March 31, 2025.
Outlook and guidance
Confident in achieving SEK 115-130 million in revenue for 2025 and SEK 300 million by next year, aiming for SEK 1 billion long-term.
Guidance for operating expenses remains at low single-digit growth for the year.
Strong demand pipeline for 2025, with further launches planned in Japan and South Korea.
U.S. tariffs expected to have limited full-year impact on gross margin, with mitigation strategies in place.
Positive outlook for European and Asian markets, with new product launches and regulatory approvals expected to drive growth.
Latest events from Senzime
- Over 90% revenue growth, improved margins, and profitability targeted for Q4 2026.SEZI
Q4 202518 Feb 2026 - Q2 sales up 76% to SEK 14.9m, driven by US growth and major new hospital contracts.SEZI
Q2 202423 Jan 2026 - Q3 sales up 90% year-over-year, driven by sensor demand and US and Asia growth.SEZI
Q3 202416 Jan 2026 - 2024 sales up 65%, next-gen TetraGraph launched, 2025 revenue set to double.SEZI
Q4 202424 Dec 2025 - 80% revenue growth, improved EBITDA, and major U.S. contracts drive strong expansion.SEZI
Q3 202510 Dec 2025 - Advanced nerve monitoring is revolutionizing anesthesia safety and driving rapid global growth.SEZI
Life Science Summit 202519 Nov 2025 - 90% sales growth, robust US momentum, and SEK 110.4M raised for expansion.SEZI
Q2 202516 Nov 2025 - Electromyography-based monitoring is rapidly becoming the new standard, driving hyper-growth and global expansion.SEZI
European Growth Conference 202512 Sep 2025